Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a development-stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome. The company was formed through a business combination in June 2021 between ARYA Sciences Acquisition Corp III and Legacy Nautilus… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nautilus Biotechnology, Inc. does
In the company’s own words
Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a development-stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome. The company was formed through a business combination in June 2021 between ARYA Sciences Acquisition Corp III and Legacy Nautilus Biotechnology, Inc., and began trading on the Nasdaq Global Select Market before transferring to the Nasdaq Capital Market in October 2025.
The company's core offering is the Nautilus Voyager platform, an integrated proteomics analysis system designed to implement the company's proprietary Iterative Mapping methodology. This single-molecule proteomic analysis platform integrates nanofabricated protein arrays, affinity reagent probing, advanced optics and fluidics, and machine learning-based analysis into an end-to-end workflow that includes instrumentation, consumables, and software. The Nautilus Voyager platform is designed to enable both broadscale proteome analysis, which identifies and quantifies a large proportion of proteins expressed in biological samples, and targeted proteoform analysis, which resolves specific protein forms and modifications that reflect functional complexity.
Nautilus addresses longstanding limitations in existing proteomics technologies, which typically require researchers to make trade-offs between breadth, depth, throughput, and reproducibility. The company believes its approach can identify and quantify approximately 95 percent of the entire proteome, including proteoforms arising from post-translational modifications. The platform generates digital protein counts designed to support consistent comparison across samples, experiments, and time.
The company employs a phased commercialization strategy beginning with research collaborations with leading biopharma companies, academic institutions, and research organizations including Genentech, the Michael J. Fox Foundation, Weill Cornell Medicine-Qatar, and The Buck Institute for Research on Aging. In January 2026, Nautilus launched its Iterative Mapping Early Access Program, providing select customers with standardized applications through Nautilus Proteomics Analysis Services.
The global proteomics market is projected to reach approximately $57 billion by 2030, representing a compound annual growth rate of approximately 13 percent. Nautilus' team combines expertise in chemistry, molecular biology, nanofabrication, engineering, machine learning, and software, with over one-third of employees holding Ph.D. degrees. The company maintains operations at its San Carlos, California facility and has established manufacturing processes combining external contract manufacturing with internal capabilities.
Company details
- Sector
- Healthcare
- Industry
- Medical Instruments
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1808805
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nautilus Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nautilus Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nautilus Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nautilus Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nautilus Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”